Reading Room Production — page 116

>) (E) >; r I >: Billet, A number of HHS OpDivs and offices, including ide any technical comments in » reviewing the bill on behalf of Please let me know w? nd fy? US. Cc: NIAID OCGR Leg @mail.nih.gov>; Auchincloss, Hugh (NIH/NIAID) [E] @niaid.nih.gov>; Harper, Jill (NIH/NIAID) [E] @niaid.nih.gov>; Parker, Marie (NIH/NIAID) [E] @niaid.nih.gov>; Billet, Courtney (NIH/NIAID) [E] @niaid.nih.gov> Subject: URGENT ACTION by 12pm Friday 7/12: TA on Risky Research Review Act Importance: High Good morning, Background HHS has been asked by the Senate Homeland Security and Governmental Affairs Committee (Chair: Sen. Gary Peters, DMI; Ranking Member: Sen. Rand Paul, R-KY) to provide technical assistance (TA) on the attached draft legislation entitled the Risky Research Review Act. The draft bill would require the establishment of an independent life sciences research security board to review federal funding for certain proposed life sciences research as defined by the bill. NIAID is mentioned briefly on page 4 in a section describing limitations on membership of the board. HHS reports that the Committee intends to consider the bill on July 24. A number of HHS OpDivs and offices, including ASPR, CDC, and FDA, have been asked to review the bill along with NIH. Action Item By noon tomorrow, Friday July 12, please review the attached draft legislation and provide any technical comments in the attached HHS TA template. Please note that NIH ORS/DOHS and NIH OSP are also reviewing the bill on behalf of NIH. As you complete your review, please keep in mind the HHS guidance on technical assistance below. Please let me know if you have any questions. Thanks, Sara To ensure that the Department's comments are given full consideration, please observe the following guidelines in providing your office's comments: 1. Are there provisions of this bill that would conflict with Department or Administration policy, and how? 2. Are there provisions that would pose difficulties for the operation or management of HHS programs, and how? 3. Are there any other significant issues that you can identify? 4. If you recommend specific changes, supply reasons and explanations, if the reasons are not obvious. For review - Risky Research Review Act Feedback Oct 2024.docx Track changes of feedback.docx For reference -redline2 NIAID comments.docx